2',3'-DIDEOXYCYTIDINE PREFERENTIALLY INHIBITS INVITRO GROWTH OF GRANULOCYTE-MACROPHAGE COLONY-FORMING CELLS FROM PATIENTS WITH CHRONIC MYELOID-LEUKEMIA

被引：3

作者：

CINATL, J ^{[1
]}

GUSSETIS, ES ^{[1
]}

NEMETH, U ^{[1
]}

MAINKE, M ^{[1
]}

KORNHUBER, B ^{[1
]}

BRENDEL, M ^{[1
]}

DOERR, HW ^{[1
]}

机构：

[1] JW GOETHE UNIV,INST MICROBIOL,DEPT HAEMATOL & ONCOL,CTR PEDIAT,FRANKFURT,GERMANY

来源：

CHEMOTHERAPY | 1991年 / 37卷 / 02期

关键词：

2'; 3'-DIDEOXYCYTIDINE; CHRONIC MYELOID LEUKEMIA; FIBRIN CLOT CULTURE; GRANULOCYTE-MACROPHAGE COLONY-FORMING CELLS;

D O I：

10.1159/000238844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effect of three nucleoside analogs, including 2-methyl-2'-deoxyadenosine (MDA), 5-amino-2'-deoxyuridine (ADU) and 2',3'-dideoxycytidine (DDC) on colony formation from unfractionated human bone marrow obtained from volunteers expressing parameters typical for normal cells (NBM) and from patients with the diagnosis of chronic myeloid leukemia (CMLBM) was observed. For the clonal growth of granulocyte-macrophage colony-forming cells (GM-CFC), a semisolid fibrin clot culture medium supplemented with 20% fetal bovine serum and 10% human placental conditioned medium was used. DDC has been shown to be at least a 10-fold more potent inhibitor for the growth of GM-CFC from CMLBM than from NBM. On the other hand, the effect of MDA and ADU on CMLBM did not differ markedly from the effect on NBM. These results suggest that DDC inhibits preferentially progenitor cells from CMLBM.

引用

页码：128 / 133

页数：6

共 19 条

[1]

BURGESS AW, 1977, BLOOD, V49, P573

[2] CHRONIC MYELOGENOUS LEUKEMIA - IS AGGRESSIVE TREATMENT INDICATED [J].

CLARKSON, B .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (02) :135-139

[3] INITIAL STUDIES ON THE CELLULAR PHARMACOLOGY OF 2',3'-DIDEOXYCYTIDINE, AN INHIBITOR OF HTLV-III INFECTIVITY [J].

COONEY, DA ;

DALAL, M ;

MITSUYA, H ;

MCMAHON, JB ;

NADKARNI, M ;

BALZARINI, J ;

BRODER, S ;

JOHNS, DG .

BIOCHEMICAL PHARMACOLOGY, 1986, 35 (13) :2065-2068

[4]

CUNNINGHAM I, 1979, BLOOD, V53, P375

[5] INVITRO BONE-MARROW TOXICITY OF NUCLEOSIDE ANALOGS AGAINST HUMAN IMMUNODEFICIENCY VIRUS [J].

INOUE, T ;

TSUSHITA, K ;

ITOH, T ;

OGURA, M ;

HOTTA, T ;

SANEYOSHI, M ;

YOSHIDA, S ;

SAITOH, H ;

TOMODA, Y ;

NAGAI, Y .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :576-579

[6] INTENSIVE COMBINATION CHEMOTHERAPY (ROAP-10) AND SPLENECTOMY IN THE MANAGEMENT OF CHRONIC MYELOGENOUS LEUKEMIA [J].

KANTARJIAN, HM ;

VELLEKOOP, L ;

MCCREDIE, KB ;

KEATING, MJ ;

HESTER, J ;

SMITH, T ;

BARLOGIE, B ;

TRUJILLO, J ;

FREIREICH, EJ .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (02) :192-200

[7] POTENTIAL ANTI-AIDS DRUGS - 2',3'-DIDEOXYCYTIDINE ANALOGS [J].

KIM, CH ;

MARQUEZ, VE ;

BRODER, S ;

MITSUYA, H ;

DRISCOLL, JS .

JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (05) :862-866

[8] GROWTH OF HUMAN ERYTHROID AND ERYTHROID-GRANULOCYTIC COLONIES IN CULTURE WITHOUT ADDITION OF EXOGENEOUS ERYTHROPOIETIN [J].

NISHIHIRA, H ;

KIGASAWA, H .

BRITISH JOURNAL OF HAEMATOLOGY, 1981, 49 (04) :563-&

[9]

OGURA M, 1985, BLOOD, V66, P1384

[10]

OGURA M, 1988, BLOOD, V72, P49

← 1 2 →